CCM
TLIS

CAAS Capital Management’s Talis Biomedical Corporation Common Stock TLIS Stock Holding History

CAAS Capital Management’s Portfolio TLIS Stock Details TLIS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2,667
Closed -$514K – 1340
2021
Q1 		$514K Buy
+2,667
New +$665K 0.01% 910

Other funds holding TLIS

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
NIP
Nicholas Investment Partners Rancho Santa Fe, California $1.39B AUM 97.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CAAS Capital Management's TLIS Position: Q2 2021 in Review

CAAS Capital Management sold out of Talis Biomedical Corporation Common Stock (TLIS) in Q2 2021, closing a stake of 2,667 shares — an estimated $514K sold.

CAAS Capital Management first reported a position in TLIS in Q1 2021 and held it in 1 quarter. The position peaked at $514K in Q1 2021. 43 funds tracked by Wall St. Rank hold TLIS as of Q2 2021.

  • CAAS Capital Management reported no remaining Talis Biomedical Corporation Common Stock position as of Q2 2021 after selling out during the quarter.
  • CAAS Capital Management sold 2,667 Talis Biomedical Corporation Common Stock shares in Q2 2021, an estimated $514K.
  • CAAS Capital Management first reported a position in Talis Biomedical Corporation Common Stock in Q1 2021 and held it in 1 quarter.
  • CAAS Capital Management's Talis Biomedical Corporation Common Stock position peaked at $514K in Q1 2021.
  • 43 funds tracked by Wall St. Rank held Talis Biomedical Corporation Common Stock as of Q2 2021.

Based on CAAS Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.